Dark eye fading composition containing camellia nitidissima extract as well as preparation method and application of dark eye fading composition

Abstract

The invention discloses a dark circle fading composition containing a golden camellia extract as well as a preparation method and application of the dark circle fading composition, and relates to the technical field of cosmetics. The composition comprises a component A, a component B and a component C, the component A comprises a common andrographis herb extract and a golden camellia extract; the component B comprises ubiquinone and a saffron crocus extract; and the component C is menthol lactate. The herba andrographitis extract, the camellia nitidissima extract, the ubiquinone, the saffron crocus extract and the menthol lactate are combined and found to have a synergistic interaction effect, and the composition formed by the components through specific compatibility can promote blood microcirculation, inhibit microangiogenesis, increase epidermal thickness and relieve cell hypoxia and eye fatigue; moreover, the eye cream is mild and non-irritating to the skin, and is suitable for people with sensitive skin to use.

Description

Technical Field

[0001] The invention relates to the technical field of cosmetics, in particular to a dark circle-lightening composition containing a golden camellia extract, and a preparation method and application thereof. Background Art

[0002] Young people today often have dark circles under their eyes due to staying up late, high stress and overuse of eyes. Most of them are vascular dark circles. Vascular dark circles are mainly caused by stagnation of blood circulation around the eyes due to rhinitis, lack of sleep, eye fatigue, endocrine disorders, anemia, etc., or thin and transparent skin under the lower eyelid, which makes the blood vessels under it clearly visible, with a blue, pink and purple appearance. Some are accompanied by swelling of the skin around the orbit.

[0003] Among the existing technologies, medical beauty technologies such as photoelectric therapy can effectively shrink and seal blood vessels and improve vascular dark circles; injection therapy can supplement the thickness of the lower eyelid and reduce blood vessel exposure. Although the effect is quick, these surgeries may be risky, accompanied by side effects and expensive. Common eye cream active ingredients such as caffeine and vitamin K have the effect of promoting blood circulation, but they all have certain skin irritation, the effect is relatively mild and the duration is short, and it is difficult to fundamentally improve vascular dark circles. Therefore, many existing technologies and products have disadvantages such as irritating ingredients, slow effects, large limitations, and high costs, and are usually difficult to adapt to the needs of different skin types.

[0004] Therefore, soothing and repairing products that reduce vascular dark circles have become a technical problem that needs to be solved urgently in this field. Summary of the invention

[0005] Based on this, the purpose of the present invention is to overcome the shortcomings of the above-mentioned prior art and provide a dark circle lightening composition containing Camellia chrysantha extract and its application. The composition can promote blood microcirculation, inhibit microangiogenesis, increase epidermal thickness, relieve cell hypoxia and eye fatigue, thereby reducing vascular dark circles, soothing redness, and strengthening the skin. It is gentle and non-irritating to the skin and is suitable for people with sensitive skin.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In a first aspect, the present invention provides a composition for lightening dark circles, the composition comprising component A, component B and component C; component A comprises Andrographis paniculata extract and Camellia chrysantha extract; component B comprises ubiquinone and saffron extract; and component C is menthol lactate.

[0008] Andrographis paniculata extract is rich in terpenoids such as andrographolide, which can inhibit angiogenesis and dilation, thereby reducing the microvessels under the eyes. Camellia chrysantha extract is rich in flavonoids and polyphenols, which can promote the repair and regeneration of skin cells, thereby increasing the thickness of the epidermis. Long-term use can reduce the visibility of blood vessels around the eyes. Ubiquinone, also known as coenzyme Q10, is a coenzyme for cellular aerobic respiration. It can enhance the energy metabolism of cells, promote the use of oxygen by cells, and relieve the hypoxia of the skin under the eyes caused by blood obstruction. Saffron extract has the effects of promoting blood circulation and removing blood stasis, dispersing depression and relieving knots, promoting microcirculation, and can relieve blood congestion under the eyes caused by staying up late, stress, and emotions. Menthyl lactate is a menthol derivative with a slight mint aroma, a long-lasting cool feeling, no burning or irritation, and can bring a gentle and long-lasting cool feeling to the skin, thereby contracting blood vessels and effectively reducing the fever and soreness caused by eye fatigue.

[0009] The present invention has found that when the above-mentioned plant extracts are used in combination with ubiquinone and menthol lactate, they can promote blood microcirculation, inhibit microangiogenesis, increase epidermal thickness, relieve cell hypoxia and eye fatigue, and achieve the effects of reducing vascular dark circles, soothing redness, and strengthening the skin. In addition, the product is mild and non-irritating to the skin and is suitable for people with sensitive skin.

[0010] As a preferred embodiment of the first aspect, the mass ratio of component A, component B and component C in the composition is component A: component B: component C = (0.6-10): (0.11-5.5): (0.001-0.05).

[0011] As a preferred embodiment of the first aspect, the mass ratio of component A, component B and component C in the composition is component A: component B: component C = (1.5-7): (0.55-3.4): (0.005-0.03).

[0012] As a preferred embodiment of the first aspect, the mass ratio of component A, component B and component C in the composition is component A: component B: component C = 4:2.2:0.01.

[0013] The present invention has found that the mass ratio of component A, component B, and component C in the composition for lightening dark circles will not only affect the VEGF reduction rate, the filaggrin increase rate, and the epidermal thickness increase rate of the composition to a certain extent, thereby affecting the composition's ability to lighten blood vessels and strengthen the skin, but also affect the composition's improvement of the redness a* value, the water content value, and the dark circle area reduction rate, thereby affecting the composition's ability to lighten dark circles, relieve redness, and moisturize. When component A, component B, and component C are further selected to be (0.6-10): (0.11-5.5): (0.001-0.05), especially (1.5-7): (0.55-3.4): (0.005-0.03), the obtained composition for lightening dark circles has better functional effects in lightening blood vessels, strengthening skin, lightening dark circles, soothing, and moisturizing; and the overall comprehensive effect of the composition is enhanced to a greater extent. It is found through research that when the mass ratio of component A, component B and component C is 4:2.2:0.01, the overall comprehensive effect of the composition of the present invention is optimal.

[0014] As a preferred embodiment of the first aspect, in the component A, the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is Andrographis paniculata extract: Camellia chrysantha extract = (0.1-5): (0.5-5).

[0015] As a preferred embodiment of the first aspect, in the component A, the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is Andrographis paniculata extract: Camellia chrysantha extract = (0.5-3): (1-4).

[0016] As a preferred embodiment of the first aspect, in the component A, the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is Andrographis paniculata extract: Camellia chrysantha extract=2:2.

[0017] The present invention has found that the mass ratio of the Andrographis paniculata extract and the Camellia chrysantha extract in component A of the composition for lightening dark circles will affect the production of vascular endothelial growth factor VEGF in the composition and the growth of filaggrin and epidermis in the skin to a certain extent, thereby affecting the ability of the composition to lighten blood vessels and strengthen the skin. When the mass ratio of the Andrographis paniculata extract and the Camellia chrysantha extract is further selected to be (0.1-5):(0.5-5), especially (0.5-3):(1-4), the efficacy of the composition in lightening blood vessels and strengthening the skin can be improved, and the overall comprehensive ability of the composition to improve vascular dark circles can be enhanced. It has been found that when the mass ratio of the Andrographis paniculata extract and the Camellia chrysantha extract is 2:2, the ability of the composition of the present invention to lighten blood vessels and strengthen the skin is the best.

[0018] As a preferred embodiment of the first aspect, in the component B, the mass ratio of ubiquinone to saffron extract is ubiquinone:saffron extract=(0.01-0.5):(0.1-5).

[0019] As a preferred embodiment of the first aspect, in the component B, the mass ratio of ubiquinone to saffron extract is ubiquinone:saffron extract=(0.05-0.4):(0.5-3).

[0020] As a preferred embodiment of the first aspect, in the component B, the mass ratio of ubiquinone to saffron extract is ubiquinone:saffron extract=0.3:1.9.

[0021] The present invention has found that the mass ratio of ubiquinone and saffron extract in component B of the composition for lightening dark circles will affect the blood circulation of the skin under the eyes of the composition to a certain extent, thereby affecting the ability of the composition to improve dark circles. When the mass ratio of ubiquinone and saffron extract is further selected to be (0.01-0.5): (0.1-5), especially (0.05-0.4): (0.5-3), the effect of promoting blood circulation and removing blood stasis, dispersing depression and unblocking knots of the composition can be improved, the ability of blood microcirculation of the skin under the eyes can be promoted, the effect of lightening dark circles can be played, and the overall comprehensive ability of the combination to improve vascular dark circles can be enhanced. It has been found that when the mass ratio of ubiquinone and saffron extract is 0.3: 1.9, the ability of the composition of the present invention to promote blood circulation and remove blood stasis, dissipate depression and unblock knots, and lighten dark circles is the best.

[0022] As a preferred embodiment of the first aspect, the method for preparing the Camellia chrysantha extract comprises the following steps: drying the flowers of Camellia chrysantha, crushing them, adding them to an aqueous solution of a low eutectic solvent, performing ultrasonic extraction, collecting the product by centrifugation, taking the supernatant, and obtaining the Camellia chrysantha extract; wherein the low eutectic solvent is composed of choline chloride solution and 1,3-propylene glycol.

[0023] As a preferred embodiment of the first aspect, the method for preparing the Camellia chrysantha extract satisfies at least one of the following requirements:

[0024] (a) the mass ratio of choline chloride to 1,3-propylene glycol is choline chloride:1,3-propylene glycol=1:(1-5);

[0025] (b) the mass concentration of the aqueous solution of the deep eutectic solvent is 60 to 90%;

[0026] (c) the temperature of the ultrasonic extraction is 40-60° C.; or / and the power of the ultrasonic extraction is 120-200 W, and the time of the ultrasonic extraction is 20-50 min;

[0027] (d) The solid-liquid ratio of the ultrasonic extraction is 1 g: (20-40) mL.

[0028] The present invention finds that different extraction methods have an impact on the camellia chrysantha extract, and affect the synergistic effect of the camellia chrysantha extract and other components, thereby affecting the ability of the composition to lighten blood vessels, improve skin blood circulation and strengthen skin, thereby affecting the comprehensive efficacy of the composition in lightening dark circles.

[0029] In a second aspect, the present invention provides use of the dark circle lightening composition as described in the first aspect in preparing cosmetics.

[0030] In a third aspect, the present invention provides an eye cream comprising the following components in percentage by mass: 1-15% of the composition, 0.05-0.5% of a thickener, 0.5-2% of a moisturizer, 5-20% of an emulsifier, 0.5-3% of a preservative, 0.01-0.3% of a pH adjuster, and the balance being deionized water.

[0031] Compared with the prior art, the beneficial effects of the present invention are:

[0032] The present invention finds from numerous plant extracts that Andrographis paniculata extract, Camellia chrysantha extract, Saffron saffron extract, ubiquinone and menthol lactate have a synergistic effect when used together. The composition formed by specific compatibility can promote blood microcirculation, inhibit microangiogenesis, increase epidermal thickness, relieve cell hypoxia and eye fatigue, and achieve the effects of reducing vascular dark circles, soothing redness, and strengthening the skin. The composition is mild and non-irritating to the skin and is suitable for people with sensitive skin. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is a comparison chart of the improvement in the area of ​​vascular dark circles of volunteers before and after use in the blank application example and application example 15 of the present invention. DETAILED DESCRIPTION

[0034] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. Its purpose is to understand the content of the present invention in detail, rather than to limit the present invention. All other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise specified, the experimental reagents and instruments designed for the implementation and comparative examples of the present invention are all commonly used ordinary reagents and instruments, which can be obtained from commercial channels. In the implementation and comparative examples, the experimental methods used are conventional methods unless otherwise specified; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch of raw materials. Further description of the raw materials used in the present invention:

[0035] Andrographis paniculata extract was purchased from Shaanxi Huike Plant Development Co., Ltd., catalog number: HKY002;

[0036] Saffron extract was purchased from Guangzhou Fanhua Biotechnology Co., Ltd., catalog number: 20220321;

[0037] Ubiquinone was purchased from Shanxi Qixin Biotechnology Co., Ltd., catalog number: QX-0516-034;

[0038] Menthyl lactate was purchased from Lvyuan Natural Fragrance Oil Refinery, Qingyuan District, Ji'an City, item number: WS-23;

[0039] White water lily extract was purchased from Shaanxi Shize Tiancheng Biotechnology Co., Ltd., catalog number: BSLTQW01;

[0040] Camellia extract was purchased from Xi’an Wanfang Biotechnology Co., Ltd., catalog number: WFSW-03;

[0041] Safflower extract was purchased from Shaanxi Shize Tiancheng Biotechnology Co., Ltd., catalog number: HHTQY01;

[0042] Menadione was purchased from Shandong Yijia Trading Co., Ltd., product number: 198;

[0043] Menthol was purchased from Lvyuan Natural Fragrance Oil Refinery, Qingyuan District, Ji'an City, item number: Mint Ice;

[0044] The preparation method of Camellia chrysantha extract-1 is as follows:

[0045] (1) Prepare a low eutectic solvent:

[0046] 30 g of choline chloride was dissolved in 90 g of 1,3-propylene glycol to obtain a low eutectic solvent; 70 g of the low eutectic solvent was dissolved in 30 g of deionized water to obtain an aqueous solution of the low eutectic solvent with a mass concentration of 70%;

[0047] (2) Preparation of Camellia chrysantha Extract:

[0048] The flowers of Camellia chrysantha are collected, cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, passed through an 80-mesh sieve, 1 g is taken, and added to the aqueous solution of the above-mentioned low eutectic solvent, with a solid-liquid ratio of 1 g: 30 mL; an ultrasonic extraction method is used, with an ultrasonic temperature of 40°C, a power of 150 W, and an extraction time of 30 min. The product is collected and centrifuged, and the supernatant is taken to obtain the Camellia chrysantha extract-1.

[0049] The preparation method of Camellia chrysantha extract-2 is as follows:

[0050] (1) Prepare a low eutectic solvent:

[0051] Dissolve 30 g of choline chloride in 30 g of 1,3-propylene glycol to obtain a low eutectic solvent, and dissolve 60 g of the low eutectic solvent in 40 g of deionized water to obtain an aqueous solution of the low eutectic solvent with a mass concentration of 60%;

[0052] (2) Preparation of Camellia chrysantha Extract:

[0053] The flowers of Camellia chrysantha were collected, cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, passed through an 80-mesh sieve, 1 g was taken, and added to the aqueous solution of the above-mentioned low eutectic solvent, with a solid-liquid ratio of 1 g: 40 mL. Ultrasonic extraction was used, with an ultrasonic temperature of 50°C, a power of 120 W, and an extraction time of 50 min. The product was collected and centrifuged, and the supernatant was taken to obtain the Camellia chrysantha extract-2.

[0054] The preparation method of Camellia chrysantha extract-3 is as follows:

[0055] (1) Prepare a low eutectic solvent:

[0056] 30 g of choline chloride was dissolved in 150 g of 1,3-propylene glycol to obtain a low eutectic solvent, 90 g of the low eutectic solvent was dissolved in 10 g of deionized water to obtain an aqueous solution of the low eutectic solvent with a mass concentration of 90%;

[0057] (2) Preparation of Camellia chrysantha Extract:

[0058] The flowers of Camellia chrysantha were collected, cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, passed through an 80-mesh sieve, 1 g was taken, and added to the aqueous solution of the above-mentioned low eutectic solvent, with a solid-liquid ratio of 1 g: 20 mL. Ultrasonic extraction was used, with an ultrasonic temperature of 60°C, a power of 200 W, and an extraction time of 20 min. The product was collected and centrifuged, and the supernatant was taken to obtain the Camellia chrysantha extract-3.

[0059] The preparation method of Camellia chrysantha extract-4 is as follows:

[0060] The flowers of Camellia chrysantha are collected, cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, and passed through an 80-mesh sieve, 1 g is taken, and an aqueous solution with a mass percentage of ethanol of 75% is added, with a solid-liquid ratio of 1 g:30 mL; an ultrasonic extraction method is used, with an ultrasonic temperature of 50°C, a power of 180 W, and an extraction time of 30 min. The product is collected and centrifuged, and the supernatant is taken to obtain the Camellia chrysantha extract-4.

[0061] The preparation method of Camellia chrysantha extract-5 is as follows:

[0062] The flowers of Camellia chrysantha are collected, cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, and passed through an 80-mesh sieve. 1 g is taken and pure water is added. The solid-liquid ratio is 1 g: 40 mL. Ultrasonic extraction is used. The ultrasonic temperature is 50°C, the power is 180 W, and the extraction time is 30 min. The product is collected and centrifuged, and the supernatant is taken to obtain the Camellia chrysantha extract-5.

[0063] The preparation method of the composition for lightening dark circles of the present invention comprises the following steps: weighing components in parts by weight, stirring and mixing evenly, and ultrasonicating for 10 minutes to obtain the composition for lightening dark circles of the eyes.

[0064] Examples and Comparative Examples

[0065] The embodiment and comparative example provide a composition for lightening dark circles under the eyes, and the components and weight portions of the composition are shown in Table 1:

[0066] Table 1:

[0067]

[0068]

[0069] Application Examples

[0070] This application example provides an eye cream, the components (mass percentage) of the eye cream are shown in Table 2; wherein the compositions used in application examples 1-19 are the compositions for lightening dark circles prepared in embodiments 1-19; the compositions used in comparative application examples 1-12 are the compositions prepared in comparative examples 1-12; for example, the composition for lightening dark circles used in application example 1 is the composition for lightening dark circles in embodiment 1, and the same can be said for the others; the composition used in application examples 20-21 is the composition for lightening dark circles prepared in embodiment 15. The composition used in comparative application examples 1-12 is the composition for lightening dark circles prepared in comparative examples 1-12, and the difference between the blank application example and the application example is that the composition of the present invention is not added. See Table 2 for details:

[0071] Table 2:

[0072]

[0073] This application example also provides a method for preparing the above-mentioned eye cream, comprising the following steps:

[0074] (1) Mix the humectant and thickener with water, heat to 85±2° C., and homogenize at 1200 rpm for 4 min. After homogenization, keep the mixture warm for later use to obtain preformed phase A.

[0075] (2) Mix the emulsifier, heat to 85±2°C, and homogenize at 1200 rpm for 4 min. After homogenization, keep warm for later use to obtain preformed phase B;

[0076] (3) Mix the preservatives and heat to 60±2°C to melt to obtain preformed phase C;

[0077] (4) Heat the preformed phase A to 80±2°C, add the preformed phase B at 250 rpm, stir and mix, then cool to 60±2°C, add the preformed phase C at 250 rpm, stir and mix, then cool to 40°C, add the dark circle lightening composition and continue stirring for 8 minutes, finally add the remaining pH adjuster to adjust the pH to 6.0, then stop stirring, discharge, and obtain the eye cream.

[0078] Effect Example 1 Cell experiment proves that the dark circles lightening composition can inhibit vascular dilation

[0079] This effect example explores the angiogenesis inhibition effect of the dark circle lightening composition prepared in Examples 1-19 and Comparative Examples 1-12:

[0080] Experimental method: The cell line used is human skin capillary endothelial cells (Beina Biotechnology), and the test conditions are: incubator temperature 37±1°C, saturated humidity, carbon dioxide 5±1%; cell culture and treatment are carried out according to the grouping, and then the test is carried out. The specific test is the determination of vascular endothelial growth factor VEGF content. The test method is as follows:

[0081] (1) The cell suspension was inoculated into a 96-well cell culture plate at a density of 2000 cells per well. 100 μL of HDMEC cell culture medium (Beina Biotechnology) was added to each well and cultured for 24 h.

[0082] (2) The supernatant was discarded, 100 μL of culture medium was added to the control group, and 100 μL of culture medium containing 0.1% of the corresponding sample (Example 1-19 and Comparative Example 1-12) was added to the experimental group, and cultured for 24 h;

[0083] (3) Collect cells separately, wash three times with PBS buffer, add 50 μL of RIPA cell lysis buffer containing protease inhibitors to each well, centrifuge the lysed samples at 12000g for 5 minutes, and collect the supernatant;

[0084] (4) Determination of vascular endothelial growth factor (VEGF) content: The vascular endothelial growth factor (VEGF) content in the cell supernatant of each group was detected using a human vascular endothelial growth factor A (VEGF-A) ELISA kit (Cat. No. BLL108277E, Baililai Biotechnology); the reduction rate of vascular endothelial growth factor (VEGF) in each example and comparative example was calculated using the following formula:

[0085] VEGF reduction rate (%) = (blank group content - sample group content) / blank group content * 100%, wherein the higher the VEGF reduction rate, the stronger the ability of the composition to inhibit blood vessels. The results are shown in Table 3.

[0086] Table 3

[0087]

[0088]

[0089] As can be seen from Table 3, the composition for lightening dark circles provided by the present invention reduces the secretion of VEGF by more than 47%, which indicates that the composition of the present invention has a strong effect of inhibiting angiogenesis.

[0090] It can be seen from Examples 1-15 and Comparative Examples 1-2 that the mass ratio of the components in the composition for lightening dark circles will affect the ability of the composition to inhibit VEGF, thereby affecting the effect of the composition in inhibiting angiogenesis.

[0091] It can be seen from Examples 1-5 that the mass ratio of the components in the composition for lightening dark circles will affect the ability of the composition to inhibit VEGF secretion. When the mass ratio of the components is limited to (0.6-10): (0.11-5.5): (0.001-0.05) of component A, component B, and component C, the obtained composition has a good effect of inhibiting angiogenesis. When the mass ratio of component A, component B, and component C is further selected to be in the range of (1.5-7): (0.55-3.4): (0.005-0.03), the obtained composition has a better effect of inhibiting angiogenesis. When the mass ratio of component A, component B, and component C is 4:2.2:0.01 (Example 5), the effect is best.

[0092] The present invention studies the influence of the mass ratio of the Andrographis extract to the Camellia chrysantha extract in component A on the ability of the composition to inhibit VEGF secretion through Examples 6-8. It can be seen from Examples 6-8 that the mass ratio of the Andrographis extract to the Camellia chrysantha extract affects the effect of the composition in inhibiting VEGF secretion, thereby affecting the efficacy of the composition in inhibiting angiogenesis. When the mass ratio of the Andrographis extract to the Camellia chrysantha extract is limited to the range of (0.1-5): (0.5-5), the ability of the composition to inhibit VEGF secretion can be improved. When the mass ratio of the Andrographis extract to the Camellia chrysantha extract is further limited to the range of (0.5-3): (1-4), the effect of the obtained composition is better. When the mass ratio of the Andrographis extract to the Camellia chrysantha extract is 2: 2 (Example 7), the effect is best.

[0093] The present invention studies the influence of the camellia chrysantha extract obtained by different extraction methods in component A on the ability of the composition to inhibit VEGF secretion through Examples 15-19. It can be seen from Examples 15-19 that the extraction method of the camellia chrysantha extract has a certain influence on the effect of inhibiting VEGF secretion, thereby affecting the angiogenesis inhibition effect of the composition. When the camellia chrysantha extract-1 is used, the angiogenesis inhibition effect of the composition obtained is the best (Example 15).

[0094] The VEGF reduction rate of Comparative Examples 1-2 is 19-23%. This is because the mass ratios of the components in the compositions of Comparative Examples 1-2 are not within the scope of the present invention, which affects the synergistic effect between the components and reduces the efficacy of the compositions.

[0095] The VEGF reduction rates of Comparative Examples 3-7 were 8-21%. This was because the lack of one of the components of the present invention in the compositions of Comparative Examples 3-7 affected the synergistic effect between the components and reduced the efficacy of the compositions.

[0096] The VEGF reduction rate of Comparative Examples 8-12 is 5-17%. This is because the compositions of Comparative Examples 8-12 replace one of the components in the combination group of the present invention with other plant extracts, which do not produce a synergistic effect with the specific components selected by the present invention, and also affect the synergistic effect between other components of the present invention, thereby reducing the efficacy of the composition.

[0097] Effect Example 2 Cell experiment proves that the prepared eye cream can increase the thickness of the epidermis

[0098] This effect example explores the repairing effect of the eye cream prepared by Application Examples 1-21, Comparative Application Examples 1-12 and Blank Application Examples.

[0099] Experimental method: The cell model used was a human 3D epidermal skin model (Guangdong Boxi Biotechnology Co., Ltd.), and the test conditions were: incubator temperature 37±1°C, saturated humidity, carbon dioxide 5±1%; 3D epidermal model culture and treatment were performed according to the grouping, and then tested. The specific tests were the determination of filaggrin (FLG) content and epidermal thickness. The test methods were as follows:

[0100] (1) The 3D epidermal skin model was cultured using EpiGrowth culture medium (Guangdong Boxi Biotechnology Co., Ltd.);

[0101] (2) Apply 25 μL of 0.1% sodium dodecyl sulfate (Sigma) on the surface of the 3D epidermal skin model and incubate for 30 min;

[0102] (3) In the blank control group, 12.5 μL of the eye cream of the blank application example was evenly applied on the surface of the epidermal model, and in the sample group, 12.5 μL of the eye cream of application examples 1-21 and comparative application examples 1-18 was applied, and cultured for 24 hours;

[0103] (4) After the incubation period, the test substance remaining on the surface of the model was cleaned with PBS solution (Biosharp), fixed with 4% paraformaldehyde (Biosharp) for 24 h, and then removed by circular cutting;

[0104] (5) Detection of FLG content: The tissues were lysed with RIPA cell lysis buffer containing protease inhibitors, and the lysed samples were centrifuged at 12000g for 5 minutes. The supernatant was taken and the FLG content of the supernatant of each group of tissues was detected using a human FLG ELISA kit (Cat. No. BLL107115E, Baililai Biotechnology);

[0105] Filaggrin (FLG) is an important molecule that connects keratin fibers in the stratum corneum of human skin. With the help of FLG monomers, keratin fibers aggregate regularly to form a solid physical barrier in the outermost layer of the epidermis, playing a role in strengthening the skin.

[0106] (6) Epidermal thickness measurement: The tissue sections were stained with H&E (Biyuntian), photographed and observed under a microscope, and the images were collected and analyzed.

[0107] The following formula was used to calculate the increase rate of the filaggrin and epidermal thickness of each embodiment and comparative example:

[0108] Increase rate (%) = (sample group - blank group) / blank group * 100%, wherein the higher the increase rate of filaggrin, the higher the increase rate of epidermal thickness, indicating that the eye cream has a stronger effect of strengthening the skin; the results are shown in Table 4:

[0109] Table 4:

[0110]

[0111]

[0112] As can be seen from Table 4, the eye cream for reducing vascular dark circles provided by the present invention increases filaggrin by more than 43% and increases epidermal thickness by more than 19%, which indicates that the eye cream with the composition added thereto of the present invention can increase epidermal thickness and play a role in strengthening the skin.

[0113] It can be seen from Application Examples 1-15 and Comparative Application Examples 1-2 that the mass ratio of the components in the composition will affect the composition's ability to generate skin filaggrin and increase epidermal thickness, thereby affecting the composition's effect of strengthening the skin.

[0114] It can be seen from Application Examples 1-5 that the mass ratio of the components in the composition affects the ability of the composition to promote the production of filaggrin and helps increase the thickness of the epidermis. When the mass ratio of the components is limited to (0.6-10): (0.11-5.5): (0.001-0.05) of component A, component B, and component C, the obtained composition has a good effect of promoting the production of filaggrin. When the mass ratio of component A, component B, and component C is further selected to be (1.5-7): (0.55-3.4): (0.005-0.03), the obtained composition has a better effect of promoting the production of filaggrin. When the mass ratio of component A, component B, and component C is 4: 2.2: 0.01 (Application Example 5), the effect is best.

[0115] The present invention studies the influence of the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract in component A on the ability of the composition to promote the production of filaggrin through application examples 6-8. It can be seen from application examples 6-8 that the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract affects the effect of the composition in promoting the production of filaggrin, thereby affecting the efficacy of the composition in strengthening the skin. When the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is limited to the range of (0.1-5):(0.5-5), the ability of the composition to promote the production of filaggrin can be improved. When the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is further limited to the range of (0.5-3):(1-4), the effect of the obtained composition is better. When the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is 2:2 (application example 7), the effect is best.

[0116] The present invention studies the influence of the camellia chrysantha extract obtained by different extraction methods in component A on the ability of the composition to increase the content of polyprotein and the thickness of the epidermis through application examples 15-19. It can be seen from application examples 15-19 that the extraction method of the camellia chrysantha extract has a certain influence on the effect of increasing the content of polyprotein and the thickness of the epidermis, thereby affecting the efficacy of the composition in increasing the content of polyprotein and the thickness of the epidermis. The effect of increasing the content of polyprotein and the thickness of the epidermis of the composition obtained when the camellia chrysantha extract-1 is used is the best (application example 15).

[0117] The increase rate of filamentous protein in comparative application examples 1-2 is 12%, and the increase rate of epidermal thickness is 3-7%. This is because the mass ratios of the components in the compositions of comparative examples 1-2 are not within the scope of the present invention, which affects the synergistic effect between the components and reduces the efficacy of the composition.

[0118] The increase rate of filamentous protein in comparative application examples 3-7 is 6-18%, and the increase rate of epidermal thickness is 2-8%. This is because the lack of one of the components of the present invention in the composition of comparative examples 3-7 affects the synergistic effect between the components and reduces the efficacy of the composition.

[0119] The increase rate of filamentous protein in comparative application examples 8-12 is 6-20%, and the increase rate of epidermal thickness is 2-7%. This is because the comparative examples 8-12 compositions replace one of the components in the combination group of the present invention with other plant extracts, which do not produce a synergistic effect with the specific components selected by the present invention, and also affect the synergistic effect between other components of the present invention, thereby reducing the efficacy of the composition.

[0120] Effect Example 3: Human skin patch test.

[0121] 30 volunteers were recruited, 15 males and 15 females, aged 20-50 years old. The closed patch test method was used. An equal amount (0.020mL-0.025mL) of the test sample (eye cream prepared by the application example, comparative application example and blank application example) was placed in a specific patch tester, and it was applied to the volunteer's arm with a low-allergenic tape, and gently pressed to evenly apply it on the skin for 24 hours; the blank control group was distilled water, and the blank application example was an eye cream without a dark circle lightening composition. After 24 hours, the patch tester was removed, and the skin reaction was observed after 0.5 hours, 24 hours, and 48 hours, and the results were recorded. The level of adverse reactions to the skin is shown in Table 5 below.

[0122] Table 5:

[0123]

[0124] After testing, the eye cream for lightening dark circles provided by Application Examples 1-21 of the present invention and Comparative Application Examples 1-12 all showed negative reactions after human patch tests, and are safe and non-irritating to human skin.

[0125] Effect Example 4 Human efficacy test on reducing vascular dark circles

[0126] This effect example explores the effect of the eye cream prepared by Application Example 1-21, Comparative Application Example 1-12, and Blank Application Example on reducing vascular dark circles.

[0127] Experimental methods:

[0128] 170 Asian adult test subjects aged 18-30 with sensitive skin and vascular dark circles were selected and randomly divided into 34 groups, with 5 people in each group. The volunteers used the samples around their eyes once in the morning and evening every day, and the data were collected on the 0th and 28th days of use;

[0129] After the visit, the volunteers washed their faces with facial cleanser and sat quietly in an air-conditioned room with a temperature of 21±1℃ and a humidity of 50±10% for 30 minutes; the researchers used VISIA-CR to photograph and analyze the dark circles under the eyes, used the CK skin color test probe CL400 to measure the redness a* value of the skin under the eyes, and used the skin moisture test probe Corneometer to measure the moisture content of the skin under the eyes.

[0130] The ability to reduce vascular dark circles is represented by the improvement in the area of ​​dark circles, the soothing ability is represented by the improvement in the redness a* value of the skin under the eyes, and the moisturizing ability is represented by the improvement in the moisture content of the skin under the eyes. The formula is as follows:

[0131] Dark circles area improvement rate = (T0 样品组 -T28 样品组 ) / T0 样品组 *100%-(T0 空白应用例 -T28 空白应用例 ) / T0 空白应用例 *100%;

[0132] Redness a* improvement rate = (T0 样品组 -T28 样品组 ) / T0 样品组 *100%-(T0 空白应用例 -T28 空白应用例 ) / T0 空白应用例 *100%;

[0133] Moisture content improvement rate = (T28 样品组 -T0 样品组 ) / T0 样品组 *100%-(T28 空白应用例 -T0 空白应用例 ) / T0 空白应用例 *100%;

[0134] The higher the improvement rate of dark circle area, the stronger the ability of the eye cream to improve or lighten dark circles; the higher the improvement rate of redness a*, the stronger the soothing ability of the eye cream; the higher the improvement rate of water content, the stronger the moisturizing and hydrating ability of the eye cream. The results are shown in Table 6:

[0135] Table 6:

[0136] Group Dark circles area improvement rate % a* value improvement rate % Moisture content improvement rate % Application Example 1 29.2 15.5 23.3 Application Example 2 29.9 15.1 22.4 Application Example 3 34.1 17.2 26.2 Application Example 4 33.9 17.4 26.1 Application Example 5 36.7 18.5 28.2 Application Example 6 38.1 19.1 29.1 Application Example 7 40.0 20.1 30.5 Application Example 8 36.6 18.5 28.0 Application Example 9 35.5 17.8 27.2 Application Example 10 40.0 20.1 30.4 Application Example 11 34.9 17.6 26.8 Application Example 12 35.3 17.8 27.3 Application Example 13 34.1 17.2 26.3 Application Example 14 33.9 17.2 26.3 Application Example 15 46.4 23.9 35.5 Application Example 16 45.1 23.3 34.6 Application Example 17 45.1 23.4 34.7 Application Example 18 43.2 22.2 33.0 Application Example 19 42.2 21.6 32.3 Application Example 20 30.3 19.2 26.1 Application Example 21 43.4 20.3 34.5 Comparative application example 1 14.0 5.9 8.5 Comparative Application Example 2 9.6 4.9 4.3 Comparative Application Example 3 10.9 5.3 7.8 Comparative Application Example 4 12.7 6.5 11.2 Comparative Application Example 5 12.7 6.0 4.5 Comparative Application Example 6 10.3 3.3 3.8 Comparative Application Example 7 14.3 5.9 9.9 Comparative Application Example 8 9.8 4.8 5.9 Comparative Application Example 9 10.1 2.1 11.4 Comparative Application Example 10 8.0 2.5 9.2 Comparative Application Example 11 8.8 4.3 11.0 Comparative Application Example 12 5.3 7.3 2.5

[0137] It can be seen from Table 6 that after 28 days of use, the eye cream for reducing vascular dark circles provided by the present invention can reduce the dark circle area by more than 29%, reduce the redness a* value by more than 15%, and increase the skin moisture content by more than 22%, which shows that the eye cream added with the composition of the present invention can play a comprehensive role in reducing dark circles, promoting skin blood circulation, soothing and moisturizing.

[0138] It can be seen from Application Examples 1-15 and Comparative Application Examples 1-2 that the mass ratio of the components in the dark circle lightening composition will affect the composition's ability to improve the area of ​​dark circles, moisture content, and a* value, thereby affecting the composition's dark circle lightening, soothing, and moisturizing effects.

[0139] It can be seen from Application Examples 1-5 that the mass ratio of the components in the composition for lightening dark circles will affect the composition's ability to lighten dark circles, promote skin blood circulation, soothe and moisturize. When the mass ratio of the components is limited to (0.6-10) of component A, component B, and component C: (0.11-5.5): (0.001-0.05), the resulting composition has good effects of lightening dark circles, promoting skin blood circulation, soothing and moisturizing. When the mass ratio of component A, component B, and component C is further selected to be within the range of (1.5-7): (0.55-3.4): (0.005-0.03), the resulting composition has a better effect. When the mass ratio of component A, component B, and component C is 4:2.2:0.01 (Application Example 5), the effect is best.

[0140] The present invention studies the influence of the mass ratio of Andrographis paniculata extract and Camellia chrysantha extract in component A on the efficacy of the composition in lightening dark circles, soothing and moisturizing through application examples 6-8. It can be seen from application examples 6-8 that the mass ratio of Andrographis paniculata extract and Camellia chrysantha extract affects the effect of the composition in lightening dark circles, soothing and moisturizing. When the mass ratio of Andrographis paniculata extract and Camellia chrysantha extract is limited to the range of (0.1-5): (0.5-5), the area improvement rate, a* value improvement rate and water content of dark circles can be improved, and the ability of the composition in lightening dark circles, soothing and moisturizing can be improved. When the mass ratio of Andrographis paniculata extract and Camellia chrysantha extract is further limited to the range of (0.5-3): (1-4), the effect of the obtained composition is better. When the mass ratio of Andrographis paniculata extract and Camellia chrysantha extract is 2:2 (application example 7), the effect is best.

[0141] The present invention studies the influence of the mass ratio of ubiquinone and saffron extract in component B on the efficacy of the composition in lightening dark circles, soothing and moisturizing by application examples 9-11. It can be seen from application examples 9-11 that the mass ratio of ubiquinone and saffron extract affects the effect of the composition in lightening dark circles, soothing and moisturizing ability. When the mass ratio of ubiquinone and saffron extract is limited to (0.01-0.5): (0.1-5) range, the area improvement rate, a* value improvement rate and water content of dark circles can be improved, and the ability of the composition to lighten dark circles, soothe and moisturize can be improved. When the mass ratio of ubiquinone and saffron extract is further limited to (0.05-0.4): (0.5-3) range, the effect of the obtained composition is better. When the mass ratio of ubiquinone and saffron extract is 0.3:1.9 (application example 10), its effect is best.

[0142] The present invention studies the influence of the mass ratio of menthol lactate in component C on the soothing and improving redness ability of the composition through application examples 12-14. It can be seen from application examples 12-14 that the mass ratio of menthol lactate can improve the a* value improvement rate, thereby affecting the soothing and improving redness effect of the composition. When the mass ratio of component A, component B and menthol lactate is limited to the range of (0.6-10): (0.11-5.5): (0.001-0.05), the soothing and improving redness ability of the composition can be improved. When the mass ratio of component A, component B and menthol lactate is further limited to the range of (1.5-7): (0.55-3.4): (0.005-0.03), the effect of the obtained composition is better. When the mass ratio of component A, component B and menthol lactate is 4: 2.2: 0.01, the effect is best.

[0143] Therefore, the optimal ratio of the components of the composition of the present invention is: Andrographis paniculata extract: Camellia chrysantha extract: Ubiquinone: Saffron extract: Menthol lactate = 2:2:0.3:1.9:0.01 (Application Example 15).

[0144] The present invention studies the influence of the camellia chrysantha extract obtained by different extraction methods in component A on the ability of the composition to lighten dark circles, soothe and moisturize through application examples 15-19. It can be seen from application examples 15-19 that the extraction method of the camellia chrysantha extract has a certain influence on the lightening dark circles, soothing and moisturizing effects. When the camellia chrysantha extract-1 is used, the composition obtained has the best lightening dark circles, soothing and moisturizing effects.

[0145] The improvement rate of dark circle area in Comparative Application Examples 1-2 is 9-14%, the improvement rate of a* value is less than 6%, and the improvement rate of moisture content is less than 10%. This is because the mass ratios of the components in the compositions of Comparative Application Examples 1-2 are not within the scope of the present invention, which affects the synergistic effect between the components and reduces the efficacy of the composition.

[0146] The improvement rate of dark circle area in comparative application examples 3-7 is 10-14%, the improvement rate of a* value is 3-6%, and the improvement rate of moisture content is 3-11%. This is because the composition of comparative application example 3-7 lacks one of the components of the present invention, which affects the synergistic effect between the components and reduces the efficacy of the composition.

[0147] The improvement rate of dark circle area in comparative application examples 8-12 is 5-10%, the improvement rate of a* value is 2-7%, and the improvement rate of moisture content is 2-11%. This is because the compositions of comparative application examples 8-12 replace one of the components in the combination group of the present invention with other plant extracts, which do not produce a synergistic effect with the specific components selected by the present invention, and also affect the synergistic effect between other components of the present invention, thereby reducing the efficacy of the composition.

[0148] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for reducing dark circles under the eyes, characterized in that: The composition comprises component A, component B and component C; The component A comprises Andrographis paniculata extract and Camellia chrysantha extract; The component B comprises ubiquinone and saffron extract; The component C is menthol lactate.

2. The composition for reducing dark circles under the eyes according to claim 1, characterized in that: The mass ratio of component A, component B and component C in the composition is component A: component B: component C = (0.6-10): (0.11-5.5): (0.001-0.05).

3. The composition for reducing dark circles under the eyes according to claim 2, characterized in that: The mass ratio of component A, component B and component C in the composition is component A: component B: component C = (1.5-7): (0.55-3.4): (0.005-0.03).

4. The composition for reducing dark circles under the eyes according to claim 1, characterized in that: In the component A, the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is Andrographis paniculata extract: Camellia chrysantha extract = (0.1-5): (0.5-5).

5. The composition for reducing dark circles under the eyes according to claim 4, characterized in that: In the component A, the mass ratio of Andrographis paniculata extract to Camellia chrysantha extract is Andrographis paniculata extract: Camellia chrysantha extract = (0.5-3): (1-4).

6. The composition for reducing dark circles under the eyes according to claim 1, characterized in that: In the component B, the mass ratio of ubiquinone to saffron extract is ubiquinone:saffron extract=(0.01-0.5):(0.1-5).

7. The composition for reducing dark circles under the eyes according to claim 6, characterized in that: In the component B, the mass ratio of ubiquinone to saffron extract is ubiquinone:saffron extract=(0.05-0.4):(0.5-3).

8. The composition for reducing dark circles under eyes according to any one of claims 1 to 7, characterized in that: The preparation method of the Camellia chrysantha extract comprises the following steps: The flowers of Camellia chrysantha are dried, crushed, added to an aqueous solution of a low eutectic solvent for ultrasonic extraction, the product is collected and centrifuged, and the supernatant is taken to obtain the Camellia chrysantha extract; wherein the low eutectic solvent is composed of choline chloride solution and 1,3-propylene glycol.

9. The composition for reducing dark circles under the eyes according to claim 8, characterized in that: Satisfy at least one of the following: (a) the mass ratio of choline chloride to 1,3-propylene glycol is choline chloride:1,3-propylene glycol=1:(1-5); (b) the mass concentration of the deep eutectic solvent in the aqueous solution of the deep eutectic solvent is 60 to 90%; (c) the temperature of the ultrasonic extraction is 40-60° C.; or / and the power of the ultrasonic extraction is 120-200 W, and the time of the ultrasonic extraction is 20-50 min; (d) The solid-liquid ratio of the ultrasonic extraction is 1 g: (20-40) mL.

10. Use of the dark circle reducing composition according to any one of claims 1 to 9 in the preparation of cosmetics.

11. An eye cream, characterized in that: The eye cream comprises the following components in percentage by mass: 1-15% of the composition of any one of claims 1-9, 0.05-0.5% of a thickener, 0.5-2% of a moisturizer, 5-20% of an emulsifier, 0.5-3% of a preservative, 0.01-0.3% of a pH adjuster, and the balance of deionized water.

Images